MOLBIO vs SUDEEPPHRM: Stock Comparison
MOLBIO DIAGNOSTICS is the larger company by market capitalisation. SUDEEP PHARMA shows a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MOLBIO leads 3; SUDEEPPHRM leads 2 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | MOLBIO | SUDEEPPHRM |
|---|---|---|
| Live Price | ₹1,302 | ₹1,101.6 |
| Day Change | -0.38% | -0.51% |
| Volume | 27.05 L | 1.51 L |
| 52-Week High | ₹1,686.8 | ₹1,378 |
| 52-Week Low | ₹926.35 | ₹524.05 |
| Distance from 52W High | -22.81% | -20.06% |
Valuation
| Metric | MOLBIO | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹15,042 Cr | ₹12,508 Cr |
| P/E Ratio | — | 69.07x |
| P/B Ratio | — | 14.3x |
| EPS | ₹4.91 | ₹3 |
| Book Value | — | ₹79.51 |
| Dividend Yield | 0% | 0.13% |
Growth
| Metric | MOLBIO | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -2.2% | -33.23% |
| Qtr Profit Growth | 7.36% | -16.65% |
Profitability & Leverage
| Metric | MOLBIO | SUDEEPPHRM |
|---|---|---|
| ROE | — | 13.11% |
| ROCE | — | 11.98% |
| Net Margin | 0% | 27.14% |
| Operating Margin | — | 45.79% |
| Debt to Equity | — | 0.16x |
Shareholding
As of Aug 2026 • change vs previous quarter| Metric | MOLBIO | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 41.29% | 76.15% |
| FII Holding | 1.51% | 1.81%▲ 0.26 pp |
| DII Holding | 16.37% | 15.65%▼ 2.46 pp |
| Public Holding | 40.82% | 6.39%▲ 2.21 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MOLBIO DIAGNOSTICS and SUDEEP PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.